Sign up to save your podcasts
Or
Share Promising Results from Beckley Psytech's ELE-101 Phase 1 Trial for Major Depressive Disorder
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Promising Results from Beckley Psytech's ELE-101 Phase 1 Trial for Major Depressive Disorder
In this episode, Atai Life Sciences co-founder and co-CEO Florian Brand discusses the promising initial results from Beckley Psytech's phase 1 trial of ELE-101 for major depressive disorder. ELE-101, an IV formulation of psilocin, aims to shorten treatment duration to two hours, with good tolerance and safety shown in phase one trials. The phase 2 trial is underway with data expected later this year. Brand also highlights the potential benefits of the two-hour treatment model for other compounds in development for depression treatment.
View all episodes
In this episode, Atai Life Sciences co-founder and co-CEO Florian Brand discusses the promising initial results from Beckley Psytech's phase 1 trial of ELE-101 for major depressive disorder. ELE-101, an IV formulation of psilocin, aims to shorten treatment duration to two hours, with good tolerance and safety shown in phase one trials. The phase 2 trial is underway with data expected later this year. Brand also highlights the potential benefits of the two-hour treatment model for other compounds in development for depression treatment.